Protea Biosciences Group, Inc. 5

5 · Protea Biosciences Group, Inc. · Filed Feb 13, 2014

Form 5

Period: 2011-12-27

Director

Transactions

Purchase
Common Stock, par value $0.0001 per share ("Common Stock")
2011-12-27$2.00/sh+50,000$100,000→ 1,569,123 total
Purchase
Common Stock
2013-07-23$0.50/sh+388,038$194,019→ 1,957,161 total
Purchase
Warrant
2011-12-27+25,000→ 933,334 total
Exercise: $2.25From: 2011-12-27Exp: 2016-12-27→ Common Stock (25,000 underlying)
Purchase
Warrant
2013-07-23+291,029→ 1,224,363 total
Exercise: $1.10From: 2013-06-30Exp: 2018-07-23→ Common Stock (291,029 underlying)
Conversion
Convertible Notes
2013-07-23$194019.00/sh−388,038$75,286,744,722→ 1,224,363 total
Exercise: $0.50From: 2013-07-23Exp: 2013-07-23→ Common Stock
Award
Stock Option
2008-05-30$150000.00/sh+100,000$15,000,000,000→ 1,324,363 total
Exercise: $1.50From: 2008-05-30Exp: 2018-05-30→ Common Stock (100,000 underlying)
Award
Stock Option
2013-03-22$120313.00/sh+218,750$26,318,468,750→ 1,209,779 total
Exercise: $0.55From: 2013-03-22Exp: 2023-03-22→ Common Stock (218,750 underlying)

Footnotes (5)

[F1]On December 27, 2011 (the "December Closing Date"), the Company issued to Scott Segal (the "Reporting Person") one unit (the "Unit"), consisting of 50,000 shares of the Company's common stock, at a price of $2.00 per share, and a warrant (the "Warrant") to purchase 25,000 shares of Common Stock at an exercise price of $2.25 per share.
[F2]On April 16, 2012, the Company issued a Convertible Promissory Note to the Reporting Person in the aggregate principal amount of $100,000. On September 25, 2012 the Company issued a convertible promissory note to the Reporting Person in the aggregate principal amount of $75,000. On March 22, 2013, the Company approved a reduction in the conversion price to $0.50 per share. On June 30, 2013, pursuant to the terms and conditions of a Conversion Agreement, dated June 18, 2013, outstanding principal and interest equal to $194,019 was converted into 388,038 shares of common stock.
[F3]Pursuant to the Conversion Agreement, upon conversion of the April Note and September Note, the Company agreed to issue a warrant to purchase 75% of the number of shares into which the notes are convertible.
[F4]Represents shares vested as of February 10, 2014.
[F5]Reflects the expiration of previously reported warrants to purchase 333,334 shares of common stock held by the Reporting Person.

Documents

1 file